RPT-Fitch affirms Novartis AG to ‘AA’, outlook stable

RPT-Fitch affirms Novartis AG to 'AA', Outlook Stable By the end of 2015, an estimated 7% of sales in 2012 are in danger from the U.S. patent expira...


RPT-Fitch affirms Novartis AG to ‘AA’, Outlook Stable
By the end of 2015, an estimated 7% of sales in 2012 are in danger from the U.S. patent expiration (with the exception of monotherapy version of Diovan). Fitch sees no patent expiry or the availability of a generic version of Diovan monotherapy to be a risk to Novartis …
Read more at

Leave a Reply